Company
Lyell Immunopharma, Inc.
Headquarters: South San Francisco, CA, United States
Employees: 188
CEO: Ms. Elizabeth Homans
Market Cap
$166.8 Million
USD as of Jan. 1, 2025
Lyell Immunopharma, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $130,000 |
| EBITDA | $-225,248,992 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | -454392.33% |
| Quarterly Revenue Growth | -100.00% |
Stocks & Indices
Lyell Immunopharma, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LYEL wb_incandescent